*Nidhi Radhakrishnan, Afiya Chogle, Rahul S. Patil, Sumi V. Pillai and Binai K. Sankar


Background: Cancer being the second leading cause of death globally, the treatment decision for cancer makes it a complex procedure. Due to its side effects and expense, selection of the appropriate drug has always been a challenge. Studies like drug utilization helps in keeping a check on rational use of these drugs by assuring maximum benefit and minimum risk. Objectives: The main objective was to assess the drug utilization of anticancer drug along with nutritional assessment and ADR severity. Methods: The observational study was conducted on subjects with cancer who satisfied the inclusion and exclusion criteria identified from the oncology department. The subjects were explained about the purpose of the study and consent was obtained. Results: Out of 137 anti-cancer drugs prescribed for 80 patients, the class of platinum derivatives were prescribed the most (34.53%) followed by taxanes (19.42%) and monoclonal antibodies (17.27%). The least commonly prescribed drugs were targeted drugs (3.60%).All the subjects included in the study were assessed for severity of adverse drug reaction using Hartwig and seigel severity scale. Out of 5 severity levels, only two of them were observed in these 80 subjects. The distribution of PG-SGA stages were analyzed and it was observed that majority of them belonged to stage C (78.57%) which is classified as malnourished, followed by stage A (22.86%) classified as well-nourished and stage B (12.86%) classified as moderately nourished. Conclusion: In our study we observed that platinum derivatives were the most commonly prescribed class of drugs compared to others, whereas, targeted drugs were less preferred.

Keywords: Cancer, drug utilization, adverse drug reaction, Nutrition.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    MAY 2023 Issue has been successfully launched on 1 MAY 2023.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction